Anti 2019-nCoV Spike Protein hIgG Antibody (C19S1-60H)

Anti 2019-nCoV Spike Protein hIgG Antibody (C19S1-60H)

  • $165.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant Human Monoclonal Antibody

Specificity :Recognizes the 2019-nCoV Spike Protein

Cited Applications :Western Blot (1:1000- 1:2000); ELISA (1:5000-1:10000)
Ideal working dilutions for each application should be empirically determined by the investigator.

Cross Reactivity :SARS-CoV Spike protein

Host / Isotype / Clone# :Human, IgG1

Stability :1yr at –20oC from date of shipment

Storage & Shipping :Store product at –20oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Product shipped on ice packs.

Scientific Background :The severe acute respiratory syndrome related novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world in 2020 (1). The spike glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2 (2), which is also known to be the key component to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) (3). A receptor binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause higher motility rate (3).

References:
1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89.

2. Xiao X, et al: The SARS-CoV S glycoprotein. Cell Mol Life Sci. 2004, 61 (19-20): 2428-30.

3. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235

Sample Data :Representative western blot with anti-2019-nCoV Spike (SC0175) Protein antibody (1:1000) using 2 µg of 2019-nCoV Spike protein RBD (C19SD-G241H).

Product Sheets (By Lot #) :

S3535-3.pdf